BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $17.00 by Analysts at Wedbush

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective decreased by analysts at Wedbush from $18.00 to $17.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Wedbush‘s price target would suggest a potential upside of 106.31% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on BCRX. Royal Bank Of Canada cut BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $13.00 to $11.00 in a report on Thursday, September 10th. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 24th. JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 30th. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.38.

BioCryst Pharmaceuticals Stock Down 3.9%

NASDAQ BCRX opened at $8.24 on Thursday. The stock’s 50-day simple moving average is $8.55 and its two-hundred day simple moving average is $8.74. BioCryst Pharmaceuticals has a twelve month low of $6.23 and a twelve month high of $11.22. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -5.49 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The firm had revenue of $180.29 million during the quarter, compared to analysts’ expectations of $165.67 million. During the same period in the prior year, the business earned $0.06 EPS. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year. On average, equities analysts expect that BioCryst Pharmaceuticals will post -2.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new stake in BioCryst Pharmaceuticals in the third quarter valued at approximately $431,000. Ethic Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 180.6% during the third quarter. Ethic Inc. now owns 34,482 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 22,193 shares during the period. Alps Advisors Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 6.5% in the third quarter. Alps Advisors Inc. now owns 338,545 shares of the biotechnology company’s stock worth $2,820,000 after purchasing an additional 20,585 shares during the last quarter. Kestra Advisory Services LLC bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth approximately $133,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth approximately $109,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Key BioCryst Pharmaceuticals News

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: BioCryst reported Q3 adjusted earnings of $0.14 per share, above the roughly $0.09 analyst consensus, and revenue of $180.29 million versus estimates of $165.67 million. Revenue rose 13.1% year over year. BioCryst Reports Third Quarter 2026 Financial Results
• Positive Sentiment: A report on the quarter says the company raised its guidance, while earnings-call coverage highlighted continued growth in ORLADEYO, its hereditary angioedema treatment. These updates support the outlook for the business. BioCryst Pharma Q3 2026: Revenue Beats and Guidance Raised BioCryst Earnings Call Highlights ORLADEYO Growth
• Neutral Sentiment: Although the reported results and guidance were favorable, the available articles do not explain why shares came under pressure. The decline may reflect market expectations or trading factors, but the reports do not establish a cause.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.